נולוג'יקס 250 מ"ג

Država: Izrael

Jezik: hebrejski

Izvor: Ministry of Health

Aktivni sastojci:

BELATACEPT 25 MG/ML

Dostupno od:

BRISTOL-MYERS SQUIBB (ISRAEL) LIMITED

ATC koda:

L04AA28

Farmaceutski oblik:

POWDER FOR CONCENTRATE FOR INFUSION

Administracija rute:

I.V

Proizveden od:

BRISTOL-MYERS SQUIBB S.R.L, ITALY

Terapijska grupa:

BELATACEPT

Terapijske indikacije:

Nulojix, in combination with corticosteroids and mycophenolic acid (MPA), is indicated for prophylaxis of graft rejection in adults receiving a renal transplant. It is recommended to add an interleukin (IL)-2 receptor antagonist for induction therapy to this belatacept-based regimen

Datum autorizacije:

2012-08-01